#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3266	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2149	440.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1680	1680	T	470	T,G	383,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3266	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2149	440.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1414	1414	C	535	C,A,T	428,1,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3266	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2149	440.5	0	HET	.	.	.	A69G,T	.	69	69	A	299	299	A	432	A,G,T	178,177,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5336	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3873	411.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1804	1804	A	479	A	393	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5336	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3873	411.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2438	2438	C	478	C,T	387,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5336	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3873	411.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2512	2512	A	516	A,C	407,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5336	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3873	411.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3064	3064	C	452	C,T	370,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	426	folP	852	852	99.88	folP.l15.c4.ctg.1	1916	66.3	0	.	p	.	0	E151K	NONSYN	451	453	GAA	947	949	AAA	104;104;102	A,C;A;A	87,1;87;85	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	426	folP	852	852	99.88	folP.l15.c4.ctg.1	1916	66.3	1	SNP	p	R228S	1	.	.	682	684	AGC	1178	1180	AGC	97;98;98	A;G;C	75;77;75	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1170	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3626	96.4	1	SNP	p	S91F	0	.	.	271	273	TCC	662	664	TCC	82;82;81	T;C;C	69;67;69	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1170	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3626	96.4	1	SNP	p	D95G	0	.	.	283	285	GAC	674	676	GAC	80;81;81	G;A;C,A	66;67;69,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1170	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3626	96.4	1	SNP	p	D95N	0	.	.	283	285	GAC	674	676	GAC	80;81;81	G;A;C,A	66;67;69,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	420	mtrR	633	633	100.0	mtrR.l6.c17.ctg.1	1693	74.1	1	SNP	p	G45D	0	.	.	133	135	GGC	631	633	GGC	107;107;108	G;G;C	84;86;85	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	224	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1416	47.4	0	.	n	.	0	A197.	DEL	197	197	A	865	865	A	94	A	77	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1108	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3194	103.8	1	SNP	p	D86N	0	.	.	256	258	GAC	721	723	GAC	134;134;135	G;A,C;C,A	109;106,1;110,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1108	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3194	103.8	1	SNP	p	S87I	0	.	.	259	261	AGT	724	726	AGT	134;134;133	A;G;T,G	105;111;108,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1108	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3194	103.8	1	SNP	p	S87W	0	.	.	259	261	AGT	724	726	AGT	134;134;133	A;G;T,G	105;111;108,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1108	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3194	103.8	1	SNP	p	S87R	0	.	.	259	261	AGT	724	726	AGT	134;134;133	A;G;T,G	105;111;108,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1108	parC	2304	2304	99.91	parC.l6.c17.ctg.1	3194	103.8	1	SNP	p	S88P	0	.	.	262	264	TCC	727	729	TCC	132;133;135	T;C;C	106;101;109	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	926	parE	1986	1986	100.0	parE.l6.c17.ctg.1	3095	88.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1904	1906	GGC	112;112;114	G;G;C	91;87;88	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	828	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2725	90.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1449	1451	GCA	133;134;134	G;C;A,C	106;108;102,1	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	828	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2725	90.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1452	1454	ATC	134;135;134	A;T;C	107;110;108	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	828	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2725	90.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1464	1466	GTG	133;131;131	G;T;G	106;99;105	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	828	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2725	90.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1464	1466	GTG	133;131;131	G;T;G	106;99;105	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	828	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2725	90.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1968	1970	ACC	87;87;87	A;C;C	69;68;70	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	828	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2725	90.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2022	2024	GCG	82;83;83	G;C,G;G	71;67,2;70	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	828	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2725	90.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2022	2024	GCG	82;83;83	G;C,G;G	71;67,2;70	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	828	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2725	90.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2145	2147	GGC	87;87;87	G;G;C,A	71;73;71,3	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	828	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2725	90.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2154	2156	GGC	88;88;88	G;G;C	70;71;73	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	828	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2725	90.7	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2172	2174	CTG	87;87;85	C;T;G	71;70;70	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1234	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3365	109.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1775	1777	CCG	95;95;94	C,T;C;G	73,1;76;73	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	528	porA	1146	1146	99.65	porA.l6.c17.ctg.1	1976	79.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	652	652	C	81	C	63	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1926	107.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	595	597	GAA	155;154;154	G;A;A	119;121;120	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1926	107.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	883	885	GAT	152;151;151	G;A,G;T	114;114,1;114	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1926	107.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1006	1008	TCA	150;150;150	T,G;C,T;A	115,2;116,1;118	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1926	107.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1135	1137	GTC	150;150;149	G;T;C	116;119;117	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1926	107.2	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1147	1149	TCT	143;143;143	T;C,A;T,G	110;110,1;109,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1926	107.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1465	1467	GCA	127;128;128	G;C,A;A	101;102,1;102	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1926	107.2	1	SNP	p	G120K	1	.	.	358	360	AAG	841	843	AAG	158;159;160	A,C;A;G	117,2;120;124	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1926	107.2	1	SNP	p	D121N	0	.	.	361	363	GAC	844	846	GAC	161;161;162	G;A,C;C	119;120,1;124	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	696	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1926	107.2	1	SNP	p	A121D	1	.	.	361	363	GAC	844	846	GAC	161;161;162	G;A,C;C	119;120,1;124	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	2138	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5058	126.1	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2082	2084	AAT	119;120;119	A,C;A;T,C	103,2;98;99,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	334	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1370	73.2	1	SNP	p	V57M	1	.	.	169	171	ATG	685	687	ATG	136;136;136	A;T;G	107;106;109	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
